Vanessa King

CEO Virion, Venture Partner

  • LocationLondon

Vanessa is CEO of Virion Biotherapeutics, an Abingworth portfolio company developing first-in-class biologics with broad spectrum antiviral activity. Prior to joining Virion, she was President and CEO of Luc Therapeutics, where she led its transformation into a precision medicine neuroscience company with a clinical pipeline. Before that, Vanessa led business development for deCODE Genetics, leading to its acquisition by Amgen in 2012 for $415 million. Vanessa has also served as Executive Chairman of Tiaki Therapeutics and held senior business development and operating positions at Amgen and Novartis. She has a PhD in Molecular Genetics from the University of Cambridge.